Cost‐effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti‐FVIII inhibitors in France - Concepedia

Concepedia

Publication | Closed Access

Cost‐effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti‐FVIII inhibitors in France

34

Citations

32

References

2020

Year

Benoı̂t Polack, Marc Trossaërt, M. Cousin, Sandrine Baffert, A. Pruvot, C. Godard

Abstract

Our results show that emicizumab is a cost-effective treatment allowing to consider an easy to implement prophylactic treatment for haemophilia A patients with anti-FVIII inhibitors.

References

	Year	Citations

Page 1